scholarly journals Modulation of Glucose Transporter Protein by Dietary Flavonoids in Type 2 Diabetes Mellitus

2015 ◽  
Vol 11 (5) ◽  
pp. 508-524 ◽  
Author(s):  
Fatemeh Hajiaghaalipour ◽  
Manizheh Khalilpourfarshbafi ◽  
Aditya Arya
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucose Transporter ◽  
Transporter Protein ◽  
Dietary Flavonoids

scholarly journals Studies of Genetic Variability of the Glucose Transporter 2 Promoter in Patients with Type 2 Diabetes Mellitus

2001 ◽  
Vol 86 (5) ◽  
pp. 2181-2186 ◽  
Author(s):  
Ann M. Møller ◽  
Niels M. Jensen ◽  
Julie Pildal ◽  
Thomas Drivsholm ◽  
Knut Borch-Johnsen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Genetic Variability ◽  
Glucose Transporter ◽  
Glucose Transporter 2

scholarly journals The rs1014290 Polymorphism of the SLC2A9 Gene Is Associated with Type 2 Diabetes Mellitus in Han Chinese

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Wan-Chun Liu ◽  
Chi-Chih Hung ◽  
Szu-Chia Chen ◽  
Ming-Yen Lin ◽  
Ling-I Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Uric Acid ◽  
Glucose Transporter ◽  
Serum Glucose ◽  
Han Chinese ◽  
Nucleotide Polymorphisms ◽  
Type 2 Dm

Aims. TheSLC2A9gene encodes the glucose transporter 9, with the abilities of transporting both glucose and uric acid and is involved in the pancreatic glucose-stimulated insulin secretion. The single nucleotide polymorphisms (SNPs) ofSLC2A9accounted for 5% variance of serum uric acid (UA). UA was identified as a risk factor for type 2 diabetes mellitus (DM). We investigated whether theSLC2A9gene variations are associated with type 2 DM in Han Chinese.Methods. Three common SNPs of theSLC2A9, rs1014290, rs2280205, and rs3733591, were genotyped in 1003 Han Chinese randomly selected from Kaohsiung, Taiwan.Results. The variant SNP rs1014290 is associated with decreased 0.12-fold risk of type 2 DM (P=.002). Per-copy increase in the minor C-allele results in 0.13 mmol/L (P=.037) and 10.03 μmol/L (P=.016) decrease in serum glucose and UA, respectively.Conclusions. The SNP rs1014290 within theSLC2A9gene is associated with type 2 DM in Han Chinese.

scholarly journals Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus

2021 ◽  
pp. 228-236
Author(s):  
I. Sh. Khalimov ◽  
Yu. Ye. Rubtsov ◽  
V. V. Salukhov ◽  
P. V. Agafonov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Diseases ◽  
Glucose Transporter ◽  
Vascular Stiffness ◽  
Vascular Aging ◽  
Glucose Transporter 2 ◽  
Vascular Age

The article discusses the pathophysiological mechanisms of the development of vascular aging as a combination of the influence on the  body of  genetic, environmental, regulatory, metabolic and other factors causing biochemical, enzymatic and cellular changes in the arterial vascular bed. The concept of “early vascular aging” and “healthy vascular aging” is defined depending on the ratio of the biological and chronological age of the vessels. The role of diabetes mellitus in increasing vascular stiffness, early vascular aging, as well as the  progression of  atherosclerotic cardiovascular diseases and their complications is considered in detail. Approaches to multifactorial management of vascular age in patients with type 2 diabetes (lifestyle modification with strategy of aggressive treatment of modifiers of atherosclerosis, rejection of bad habits, adherence to dietary recommendations and the use of modern organo- and vasoprotective antidiabetic drugs) are revealed. The mechanism of realization of vasoprotective effects of inhibitors of sodium-glucose transporter-2 (iNGLT-2) is described in detail. The results of completed large random ized trials EMPA-REG Outcome and EMPA-REG BP of the most studied representative of the IGLT-2 group, empagliflozin, are presented. It has been shown that due to their glucose and natriuretic effects, the ability to reduce body weight and blood pressure, improve myocardial metabolism and bioenergetics, decrease the activity of the sympathetic nervous system, as well as positive effects on vascular stiffness, NGLT-2 inhibitors are the drugs of choice in patients with type 2 diabetes mellitus (T2DM) and cardiovascular diseases. This makes it possible to widely use this group of drugs for managing the vascular age of patients and represents a new opportunity in the prevention of vascular aging in T2DM. 

scholarly journals Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Alaaeldin Bashier ◽  
Azza Bin Hussain ◽  
Elamin Abdelgadir ◽  
Fatheya Alawadi ◽  
Hani Sabbour ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Diseases ◽  
High Risk ◽  
Glucose Transporter ◽  
Lifestyle Modification ◽  
Patient Specific ◽  
Consensus Recommendation

Abstract The recent American Diabetes Association and the European Association for the Study of Diabetes guideline mentioned glycaemia management in type 2 diabetes mellitus (T2DM) patients with cardiovascular diseases (CVDs); however, it did not cover the treatment approaches for patients with T2DM having a high risk of CVD, and treatment and screening approaches for CVDs in patients with concomitant T2DM. This consensus guideline undertakes the data obtained from all the cardiovascular outcome trials (CVOTs) to propose approaches for the T2DM management in presence of CV comorbidities. For patients at high risk of CVD, metformin is the drug of choice to manage the T2DM to achieve a patient specific HbA1c target. In case of established CVD, a combination of glucagon-like peptide-1 receptor agonist with proven CV benefits is recommended along with metformin, while for chronic kidney disease or heart failure, a sodium–glucose transporter proteins-2 inhibitor with proven benefit is advised. This document also summarises various screening and investigational approaches for the major CV events with their accuracy and specificity along with the treatment guidance to assist the healthcare professionals in selecting the best management strategies for every individual. Since lifestyle modification and management plays an important role in maintaining the effectiveness of the pharmacological therapies, authors of this consensus recommendation have also briefed on the patient-centric non-pharmacological management of T2DM and CVD.

Sign in / Sign up

Export Citation Format

Share Document